Hypertension and Diabetic Kidney Disease - Prevalence, current treatment and future options

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2005-10-25

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The increase in diabetic kidney disease is a worldwide problem. Current treatment centers on antihypertensives inhibitors for the renin-angiotensin system and merely retards the decline of renal function. A large unmet need thus exists for therapies that fully halt disease progression or provide curative benefit


Scope

  • The prevalence and progression of diabetic nephropathy in the seven major markets is evaluated
  • The foremost pharmacological strategies for the treatment of diabetic nephropathy are reviewed
  • The current status of angiotensin II receptor blockade as first line therapy in the treatment of diabetic nephropathy is discussed
  • An overview is given of the drugs in development for the treatment of diabetic nephropathy


    • Report Highlights
    The necessity for aggressive blood pressure control is undisputed in the medical community, but the therapeutic focus is now extending to end-organ protection as a treatment goal of equal importance to BP reduction. Thus, commercial performance of both ACE inhibitors and ARBs is dependent on renoprotective benefits beyond blood pressure control

    The pipeline for developmental drugs targeting the cause of diabetic kidney disease is dominated by endothelin receptor antagonists and advanced glycosylation end product inhibitors. The commercial potential for successful new agents is substantial as existing therapies do not halt the progression of diabetic nephropathy to end stage renal disease

    Proximal blockade of the renin-angiotensin system (RAS) through renin inhibition offers greater treatment opportunities than distal inhibition via angiotensin II receptor blockade. Recent basic and clinical research supports the strong theoretical appeal of renin inhibition as the most promising pharmacological strategy in the short-to-medium term


    Reasons to Purchase

  • Explore the growing burden of ESRD on healthcare systems through data on the prevalence and progression of diabetic nephropathy
  • Assess the potential of current treatment options in the diabetic nephropathy arena
  • Identify novel R&D compounds in the diabetic nephropathy pipeline

    • Table of Contents

    Other users found this report page using the following search terms: hypertension antihypertensive blood pressure renal failure kidney disease esrd diabetic disease kidney hypertension nephropathy prevalence treatment future renal hypertensive

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.